Imricor Medical Systems (ASX:IMR) signed a license agreement with Swiss software company Adis SA to commercialize artificial intelligence (AI) modules integrated within its NorthStar 3D mapping system, according to a Thursday filing with the Australian bourse.
The company will provide NorthStar AI modules as software license options, sharing upfront and ongoing revenue with ADIS under the deal, the filing said.
NorthStar and AI modules are undergoing regulatory processes for commercial sale, with plans for launch in Europe, the US, and the Middle East in 2025.
The first module the companies are targeting is one for providing automatic heart segmentation capabilities to NorthStar, which is expected to save time during interventional cardiovascular magnetic resonance procedures by creating 3D anatomical shells of heart chambers from standard MRI images, according to the filing.
Financial terms of the deal were not disclosed.
Imricor Medical Systems shares rose almost 15% in morning trade Thursday and earlier hit their highest since November 2021.
Price (AUD): $1.23, Change: $+0.16, Percent Change: +14.95%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。